OncoMatch/Clinical Trials/NCT07174063

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Is NCT07174063 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JSB462 for metastatic prostate cancer (mcrpc).

Phase 1RecruitingNovartis PharmaceuticalsNCT07174063Data as of May 2026

Treatment: JSB462 — This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify